Ankündigung • Jun 30
Vcanbio Cell & Gene Engineering Corp., Ltd to Report First Half, 2026 Results on Aug 31, 2026 Vcanbio Cell & Gene Engineering Corp., Ltd announced that they will report first half, 2026 results on Aug 31, 2026 Reported Earnings • Apr 25
First quarter 2026 earnings released: EPS: CN¥0.05 (vs CN¥0.06 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.05 (down from CN¥0.06 in 1Q 2025). Revenue: CN¥317.3m (down 9.5% from 1Q 2025). Net income: CN¥24.2m (down 14% from 1Q 2025). Profit margin: 7.6% (down from 8.0% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Ankündigung • Apr 25
Vcanbio Cell & Gene Engineering Corp., Ltd, Annual General Meeting, May 18, 2026 Vcanbio Cell & Gene Engineering Corp., Ltd, Annual General Meeting, May 18, 2026, at 09:30 China Standard Time. Location: No. 12, Meiyuan Road, Huayuan Industrial Zone, Binhai High-tech Zone, Tianjin China Ankündigung • Mar 30
Vcanbio Cell & Gene Engineering Corp., Ltd to Report Q1, 2026 Results on Apr 25, 2026 Vcanbio Cell & Gene Engineering Corp., Ltd announced that they will report Q1, 2026 results on Apr 25, 2026 Ankündigung • Dec 26
Vcanbio Cell & Gene Engineering Corp., Ltd to Report Fiscal Year 2025 Results on Apr 25, 2026 Vcanbio Cell & Gene Engineering Corp., Ltd announced that they will report fiscal year 2025 results on Apr 25, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: CN¥0.11 (vs CN¥0.11 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.11. Revenue: CN¥376.1m (down 6.8% from 3Q 2024). Net income: CN¥50.1m (up 3.7% from 3Q 2024). Profit margin: 13% (up from 12% in 3Q 2024). The increase in margin was driven by lower expenses. Ankündigung • Sep 30
Vcanbio Cell & Gene Engineering Corp., Ltd to Report Q3, 2025 Results on Oct 30, 2025 Vcanbio Cell & Gene Engineering Corp., Ltd announced that they will report Q3, 2025 results on Oct 30, 2025 New Risk • Sep 06
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Ankündigung • Jun 30
Vcanbio Cell & Gene Engineering Corp., Ltd to Report First Half, 2025 Results on Aug 29, 2025 Vcanbio Cell & Gene Engineering Corp., Ltd announced that they will report first half, 2025 results on Aug 29, 2025 Reported Earnings • Apr 25
First quarter 2025 earnings released: EPS: CN¥0.06 (vs CN¥0.09 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.06 (down from CN¥0.09 in 1Q 2024). Revenue: CN¥350.8m (down 12% from 1Q 2024). Net income: CN¥28.0m (down 30% from 1Q 2024). Profit margin: 8.0% (down from 10% in 1Q 2024). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Ankündigung • Apr 25
Vcanbio Cell & Gene Engineering Corp., Ltd, Annual General Meeting, May 20, 2025 Vcanbio Cell & Gene Engineering Corp., Ltd, Annual General Meeting, May 20, 2025, at 14:00 China Standard Time. Location: No. 12, Meiyuan Road, Huayuan Industrial Zone, Binhai High-tech Zone, Tianjin China Ankündigung • Mar 28
Vcanbio Cell & Gene Engineering Corp., Ltd to Report Q1, 2025 Results on Apr 25, 2025 Vcanbio Cell & Gene Engineering Corp., Ltd announced that they will report Q1, 2025 results on Apr 25, 2025 Ankündigung • Dec 27
Vcanbio Cell & Gene Engineering Corp., Ltd to Report Fiscal Year 2024 Results on Apr 25, 2025 Vcanbio Cell & Gene Engineering Corp., Ltd announced that they will report fiscal year 2024 results on Apr 25, 2025 Reported Earnings • Oct 31
Third quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.099 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.11. Revenue: CN¥403.6m (flat on 3Q 2023). Net income: CN¥48.3m (down 3.0% from 3Q 2023). Profit margin: 12% (in line with 3Q 2023). Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Ankündigung • Sep 30
Vcanbio Cell & Gene Engineering Corp., Ltd to Report Q3, 2024 Results on Oct 30, 2024 Vcanbio Cell & Gene Engineering Corp., Ltd announced that they will report Q3, 2024 results on Oct 30, 2024 Reported Earnings • Aug 30
Second quarter 2024 earnings released: EPS: CN¥0.09 (vs CN¥0.10 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.09 (down from CN¥0.10 in 2Q 2023). Revenue: CN¥404.3m (down 3.8% from 2Q 2023). Net income: CN¥45.0m (flat on 2Q 2023). Profit margin: 11% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Ankündigung • Jun 28
Vcanbio Cell & Gene Engineering Corp., Ltd to Report First Half, 2024 Results on Aug 30, 2024 Vcanbio Cell & Gene Engineering Corp., Ltd announced that they will report first half, 2024 results on Aug 30, 2024 Valuation Update With 7 Day Price Move • May 16
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥18.43, the stock trades at a trailing P/E ratio of 77.9x. Average trailing P/E is 39x in the Biotechs industry in China. Total loss to shareholders of 20% over the past three years. Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.09 (vs CN¥0.08 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.09 (up from CN¥0.08 in 1Q 2023). Revenue: CN¥398.0m (up 5.4% from 1Q 2023). Net income: CN¥40.1m (up 7.4% from 1Q 2023). Profit margin: 10% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Ankündigung • Apr 27
Vcanbio Cell & Gene Engineering Corp., Ltd, Annual General Meeting, May 20, 2024 Vcanbio Cell & Gene Engineering Corp., Ltd, Annual General Meeting, May 20, 2024, at 09:30 China Standard Time. Location: No. 12, Meiyuan Road, Huayuan Industrial Zone, Binhai High-tech Zone, Tianjin China Ankündigung • Mar 30
Vcanbio Cell & Gene Engineering Corp., Ltd to Report Q1, 2024 Results on Apr 26, 2024 Vcanbio Cell & Gene Engineering Corp., Ltd announced that they will report Q1, 2024 results on Apr 26, 2024 Ankündigung • Feb 19
Vcanbio Cell & Gene Engineering Corp., Ltd (SHSE:600645) announces an Equity Buyback for CLP 200 million worth of its shares. Vcanbio Cell & Gene Engineering Corp., Ltd (SHSE:600645) announces a share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its Class A shares. The company will use CNY 100 million for the equity incentive and CNY 100 million for maintaining company value and shareholder rights. The shares will be repurchased at no more than CNY 22 per share. The plan will be valid for 3 months for maintaining company value and shareholder rights and 12 months for equity incentives. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥14.63, the stock trades at a trailing P/E ratio of 52.3x. Average trailing P/E is 32x in the Biotechs industry in China. Total loss to shareholders of 12% over the past three years. Ankündigung • Dec 30
Vcanbio Cell & Gene Engineering Corp., Ltd to Report Fiscal Year 2023 Results on Apr 26, 2024 Vcanbio Cell & Gene Engineering Corp., Ltd announced that they will report fiscal year 2023 results on Apr 26, 2024 Ankündigung • Sep 30
Vcanbio Cell & Gene Engineering Corp., Ltd to Report Q3, 2023 Results on Oct 28, 2023 Vcanbio Cell & Gene Engineering Corp., Ltd announced that they will report Q3, 2023 results at 3:00 PM, China Standard Time on Oct 28, 2023 Reported Earnings • Apr 26
First quarter 2023 earnings released: EPS: CN¥0.08 (vs CN¥0.08 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.08 (in line with 1Q 2022). Revenue: CN¥377.7m (down 4.2% from 1Q 2022). Net income: CN¥37.4m (up 4.3% from 1Q 2022). Profit margin: 9.9% (in line with 1Q 2022). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 29
Third quarter 2022 earnings released: EPS: CN¥0.098 (vs CN¥0.17 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.098 (down from CN¥0.17 in 3Q 2021). Revenue: CN¥407.4m (up 4.0% from 3Q 2021). Net income: CN¥49.7m (down 38% from 3Q 2021). Profit margin: 12% (down from 21% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 31
Second quarter 2022 earnings released: EPS: CN¥0.061 (vs CN¥0.14 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.061 (down from CN¥0.14 in 2Q 2021). Revenue: CN¥374.6m (down 6.7% from 2Q 2021). Net income: CN¥29.0m (down 56% from 2Q 2021). Profit margin: 7.7% (down from 16% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 27
First quarter 2022 earnings released: EPS: CN¥0.08 (vs CN¥0.10 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.08 (down from CN¥0.10 in 1Q 2021). Revenue: CN¥394.2m (up 7.5% from 1Q 2021). Net income: CN¥35.8m (down 21% from 1Q 2021). Profit margin: 9.1% (down from 12% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.11 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥391.7m (up 12% from 3Q 2020). Net income: CN¥80.1m (up 55% from 3Q 2020). Profit margin: 21% (up from 15% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Reported Earnings • Aug 30
Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.22 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥401.4m (up 17% from 2Q 2020). Net income: CN¥65.2m (down 13% from 2Q 2020). Profit margin: 16% (down from 22% in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 25
Full year 2020 earnings released: CN¥0.27 loss per share (vs CN¥0.11 profit in FY 2019) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: CN¥1.32b (down 4.9% from FY 2019). Net loss: CN¥126.9m (down 355% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Feb 03
New 90-day low: CN¥17.68 The company is down 28% from its price of CN¥24.41 on 05 November 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period. Is New 90 Day High Low • Jan 11
New 90-day low: CN¥18.06 The company is down 31% from its price of CN¥26.28 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period. Is New 90 Day High Low • Dec 24
New 90-day low: CN¥19.60 The company is down 23% from its price of CN¥25.39 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. Is New 90 Day High Low • Nov 25
New 90-day low: CN¥22.73 The company is down 23% from its price of CN¥29.60 on 27 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 11% over the same period. Reported Earnings • Nov 03
Third quarter 2020 earnings released: EPS CN¥0.11 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: CN¥349.9m (up 3.8% from 3Q 2019). Net income: CN¥51.8m (up 71% from 3Q 2019). Profit margin: 15% (up from 9.0% in 3Q 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Ankündigung • Oct 29
Vcanbio Cell & Gene Engineering Corp., Ltd to Report Q3, 2020 Results on Oct 31, 2020 Vcanbio Cell & Gene Engineering Corp., Ltd announced that they will report Q3, 2020 results on Oct 31, 2020 Is New 90 Day High Low • Oct 22
New 90-day low: CN¥24.35 The company is down 1.0% from its price of CN¥24.52 on 24 July 2020. The Chinese market is also down 1.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is down 10.0% over the same period. Ankündigung • Sep 21
Tianjin Development Zone Deyuan Investment Development Co., Ltd. completed the acquisition of 16.06% stake in Zhongyuan Union Stem Cell Bioengineering Co., Ltd. (SHSE:600645) from Union Health Medical-Pharmaceutical Industry Development Co., Ltd. Tianjin Development Zone Deyuan Investment Development Co., Ltd. agreed acquire 16.06% stake in Zhongyuan Union Stem Cell Bioengineering Co., Ltd. (SHSE:600645) from Union Health Medical-Pharmaceutical Industry Development Co., Ltd. for approximately CNY 150 million on February 9, 2007. Tianjin Development Zone Deyuan Investment Development Co., Ltd. will acquire 68.19 million shares. On February 9, 2007, Tianjin Development Zone Deyuan Investment Development Co., Ltd. acquired 68 million shares of Zhongyuan Union Stem Cell Bioengineering Co., Ltd.
Tianjin Development Zone Deyuan Investment Development Co., Ltd. completed the acquisition of 16.06% stake in Zhongyuan Union Stem Cell Bioengineering Co., Ltd. (SHSE:600645) from Union Health Medical-Pharmaceutical Industry Development Co., Ltd. on March 27, 2007. Tianjin Development Zone Deyuan Investment Development Co., Ltd. acquired remaining 0.19 million shares. Ankündigung • Jul 17
Vcanbio Cell & Gene Engineering Corp., Ltd to Report First Half, 2020 Results on Aug 29, 2020 Vcanbio Cell & Gene Engineering Corp., Ltd announced that they will report first half, 2020 results on Aug 29, 2020 
